sweelin® is now FDA GRAS Approved, Clearing the Path for Accelerated U.S. Commercialization
Amai Proteins announces a major milestone for sweelin® in the U.S. market. The U.S. FDA has completed its review of the GRAS (Generally Recognized as Safe) notice for sweelin® and confirmed it has no safety concerns regarding the use of sweelin® as...
Amai Proteins succesfully completed world's first human clinical trial on effects of sweet proteins, with sweelin®
REHOVOT, Israel, Dec. 17, 2024 /PRNewswire/ -- Amai Proteins, a scale-up designer of novel proteins that answer the needs of consumers and industry, has succesfullly completed world's first double-blind, random clinical trial on the effects of their...